Save time and get answers to complex questions with AI chat
What are the liver enzyme requirements for starting terbinafineWhen does the apixaban patent expire?When does the patent expire on ibranceAdefovir dipivoxil discount cardIs liver function monitoring necessary with lipitor
See the DrugPatentWatch profile for Koselugo
The FDA approval date for Koselugo (selumetinib) is April 10, 2020. [1]
That FDA approval was for pediatric patients aged 2 years and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas. [1]
Koselugo’s original FDA approval is tied to the indication above. If you’re checking a specific expanded indication or label change, the date can differ from the initial approval date. DrugPatentWatch.com lists regulatory and patent-related details that can help distinguish approvals vs. later label updates. [2] Sources: [1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212089 [2] https://www.drugpatentwatch.com/
Other Questions About Koselugo :